Table 2.

Change in the values of the main biomarkers 7–10 days after the beginning of the tofacitinib use. Point 1 was 1–3 days before the beginning of the tofacitinib use or equivalent days in the group CON. Point 2 was 7–10 days after the beginning of tofacitinib use or equivalent days in group CON.

Group	Group TOF (n = 32)			Group CON (n = 30)			p	p
Point	1	2	pa	1	2	pa	1	2
Lung lesion volume, %	44 [34–63]	38 [28–50]	0.022	44 [35–63]	38 [37–63]	0.760	0.762	0.457
C-reactive protein, mg/L	95 [73–140]	7 [3–22]	<0.001	110 [94–131]	20 [5–52]	0.001	0.458	0.048
Oxygen saturation, %	93 [91–95]	96 [91–98]	0.012	92 [87–95]	92 [82–97]	0.561	0.200	0.073
Body temperature, 0C	36.9 [36.7–38.0]	36.6 [36.4–36.7]	<0.001	37.5 [36.7–38.0]	36.6 [36.4–36.7]	<0.001	0.402	0.857
White blood cells, 109/L	6.9 [4.9–10.7]	9.1 [7.3–13.1]	0.001	7.0 [5.7–8.9]	10.7 [7.0–14.1]	0.001	0.927	0.773
Neutrophils, 109/L	5.2 [3.7–6.6]	6.4 [4.5–10.8]	0.009	5.3 [4.2–7.8]	7.5 [4.2–12.0]	0.005	0.442	0.767
Lymphocytes, 109/L	1.2 [0.7–1.7]	1.7 [0.9–2.1]	0.161	0.9 [0.7–1.2]	1.3 [0.5–2.2]	0.010	0.098	0.477
Platelets, 109/L	194 [165–283]	275 [219–364]	0.007	224 [189–254]	233 [140–440]	0.154	0.577	0.434
Creatinine, μmol/L	102 [92–115]	91 [74–104]	<0.001	93 [83–110]	84 [73–97]	0.090	0.156	0.519
ALT, U/L	36 [19–66]	46 [27–87]	0.147	44 [24–59]	54 [35–81]	0.048	0.606	0.947
LDH, U/L	518 [396–824]	415 [372–570]	0.019	663 [474–978]	511 [354–957]	0.440	0.205	0.336
Supplemental oxygen	22 (68.8%)	15 (46.7%)	0.076	20 (66.7%)	9 (30.0%)	0.005	0.861	0.173
Mechanical ventilation	0 (0.0%)	0 (0.0%)	–	0 (0.0%)	8 (26.7%)	0.002	–	0.002
No respiratory support	10 (31.2%)	17 (53.1%)	0.076	10 (33.3%)	13 (43.3%)	0.426	0.861	0.441
Prone position	7 (21.9%)	6 (18.8%)	0.756	2 (6.7%)	10 (33.3%)	0.010	0.089	0.190

ALT - Alanine aminotransferase; AST - Asparaginaminotransferase; LDH - Lactate dehydrogenase; ICU - intensive care unit.

*- Interleukin 6 was not tested in all included patients.

^a- Difference between points 1 and 2.